Zobrazeno 1 - 10
of 5 233
pro vyhledávání: '"trametinib"'
Autor:
Aram A. Musaelyan, Ekaterina M. Anokhina, Alina I. Turdubaeva, Natalia V. Mitiushkina, Anastasia N. Ershova, Anna D. Shestakova, Aigul R. Venina, Evgeny N. Imyanitov, Sergey V. Orlov
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 3, Pp 780-788 (2024)
Systemic chemotherapy is the main treatment option for patients with advanced intrahepatic cholangiocarcinoma (iCCA), however, its efficacy is limited. Herein, we report a young patient with NRAS-mutated chemoresistant metastatic iCCA, who received s
Externí odkaz:
https://doaj.org/article/15c6b988128b481890e948ca980a13a8
Autor:
Afrodité Németh, Gréta L. Bányai, Nikolett K. Dobos, Tamás Kós, Anikó Gaál, Zoltán Varga, Edit I. Buzás, Delaram Khamari, Magdolna Dank, István Takács, A. Marcell Szász, Tamás Garay
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Extracellular vesicles (EVs) constitute a vital component of intercellular communication, exerting significant influence on metastasis formation and drug resistance mechanisms. Malignant melanoma (MM) is one of the deadliest forms of skin ca
Externí odkaz:
https://doaj.org/article/82cfcaeb75a74849a5be0051bae737b3
Autor:
Emmanuel Seront, Antoine Froidure, Nicole Revencu, Valerie Dekeuleneer, Philippe Clapuyt, Dana Dumitriu, Miikka Vikkula, Laurence M. Boon
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-6 (2024)
Abstract Repurposing anticancer drugs to vascular malformations has significantly improved patient outcomes. Complex Lymphatic Anomalies (CLA) are part of the spectrum of lymphatic malformations (LMs) that share similar oncogenic mutations to cancer.
Externí odkaz:
https://doaj.org/article/27565a7accc341e589e0e8225fd143af
Autor:
Ander Puyalto, María Rodríguez-Remírez, Inés López, Irati Macaya, Elizabeth Guruceaga, María Olmedo, Anna Vilalta-Lacarra, Connor Welch, Sergio Sandiego, Silvestre Vicent, Karmele Valencia, Alfonso Calvo, Ruben Pio, Luis E. Raez, Christian Rolfo, Daniel Ajona, Ignacio Gil-Bazo
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-19 (2024)
Abstract Background The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on Id1 protein, a ke
Externí odkaz:
https://doaj.org/article/a7f566efdb754d68bd28062af5ab4148
Autor:
Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Zhou, Xin Wang, Zhong Wu, Bing Peng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is not sensitive to most chemotherapy drugs, leading to poor chemotherapy efficacy. Recently, Trametinib and Palbociclib have promising prospects in the treatment of pancreatic cancer. This article aim
Externí odkaz:
https://doaj.org/article/677acbb956ea4a74afd45acba5093f15
Autor:
Takako Inoue, Kei Kunimasa, Motohiro Tamiya, Takahisa Kawamura, Toshiyuki Minami, Kazumi Nishino
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 929-933 (2024)
Abstract We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progre
Externí odkaz:
https://doaj.org/article/8d66f6c5b4744281b900c0ad4f7f6b80
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Clonal MAPK-pathway activating mutations in the MAP2K1 (MEK1) gene are present in approximately 9% of cutaneous melanomas. These mutations are divided into three classes: RAF-dependent, RAF-regulated, RAF-independent. Cell lines with class-2 or RAF-r
Externí odkaz:
https://doaj.org/article/9410ea379ac04ebfb681528f83149b7c
Autor:
Athanasios Oikonomou, Titus Watrin, Luigia Valsecchi, Katerina Scharov, Angela Maria Savino, Julian Schliehe-Diecks, Michela Bardini, Grazia Fazio, Silvia Bresolin, Andrea Biondi, Arndt Borkhardt, Sanil Bhatia, Giovanni Cazzaniga, Chiara Palmi
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e34033- (2024)
Combining multiple drugs broadens the window of therapeutic opportunities and is crucial for diseases that are currently lacking fully curative treatments. A powerful emerging tool for selecting effective drugs and combinations is the high-throughput
Externí odkaz:
https://doaj.org/article/fd7162de2418411eab383592f62779c1
Autor:
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Shinji Takeuchi
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
We report a case of limited effectiveness of dabrafenib and trametinib in a 59-year-old man with poorly differentiated lung carcinoma and a rare BRAF K601E mutation. The patient, unresponsive to chemotherapy and immunotherapy, received these targeted
Externí odkaz:
https://doaj.org/article/67c78e62172b42b580e93f5cade774a9
Publikováno v:
Thoracic Cancer, Vol 15, Iss 18, Pp 1454-1456 (2024)
Abstract Although dabrafenib plus trametinib has been approved for BRAF V600E mutation positive advanced non‐small cell lung cancer (NSCLC), data on its efficacy against uncommon BRAF mutations are still limited due to their rare frequency. We repo
Externí odkaz:
https://doaj.org/article/8304f5f801794ef8a5a47c81e64fabd0